Lucid Diagnostics (NASDAQ:LUCD) Receives “Buy” Rating from Needham & Company LLC

Posted by Caroline Horne on Nov 17th, 2024

Needham & Company LLC reissued their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $2.50 target price on the stock.

LUCD has been the topic of several other reports. Ascendiant Capital Markets cut their price target on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a report on Tuesday, September 10th. Canaccord Genuity Group reiterated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group upgraded shares of Lucid Diagnostics to a “strong-buy” rating in a report on Tuesday, August 13th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Lucid Diagnostics presently has a consensus rating of “Buy” and an average target price of $3.69.

Read Our Latest Research Report on LUCD

Lucid Diagnostics Trading Down 2.3 %

Shares of NASDAQ:LUCD opened at $0.99 on Thursday. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.58. The firm’s 50-day moving average is $0.87 and its 200 day moving average is $0.85.

Institutional Trading of Lucid Diagnostics

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC lifted its holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) by 66.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 34,671 shares of the company’s stock after acquiring an additional 13,835 shares during the quarter. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 as of its most recent SEC filing. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.